Circulating CA125 in Patients with Peritoneal Mesothelioma Treated with Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion
- 151 Downloads
Recent phase I/II trials report encouraging results in selected patients with peritoneal mesothelioma (PM) treated with cytoreductive surgery (CRS) and intraperitoneal hyperthermic perfusion (IPHP). Circulating tumor markers have never been extensively investigated in the management of PM. We assessed the clinical role of markers in a large series of patients with PM undergoing CRS and IPHP.
Clinical data on 60 patients with PM operated with the intention to perform adequate CRS (residual tumor nodules ≤ 2.5mm) and IPHP were prospectively collected. Marker levels were determined pre-operatively, post-operatively, and routinely during long-term follow-up. Baseline diagnostic sensitivity, accuracy in monitoring response to treatment or tumor progression and prognostic significance were determined.
Baseline diagnostic sensitivity was 53.3% for CA125, 0 for CEA, 3.8% for CA19.9 and 48.5% for CA15.3. Forty-six patients underwent adequate cytoreduction and IPHP; gross residual tumor was left after the operation in fourteen. Postoperatively, CA125 became negative in 21/22 patients with elevated baseline levels undergoing adequate CRS and IPHP, while remained elevated in 9/9 patients with persistent macroscopic disease. CA125 became positive in 12/12 patients with elevated baseline levels developing disease progression after adequate CRS and IPHP. Baseline CA125 showed borderline prognostic significance only among patients not previously treated with systemic chemotherapy.
CA125 was elevated in the majority of patients with PM in the present series. Serial maker measurements paralleled tumor growth or regression after CRS and IPHP, suggesting the need of further studies to assess the role of CA125 in this clinical setting.
KeywordsCA125 Peritoneal mesothelioma Peritonectomy Intraperitoneal hyperthermic perfusion Serum tumor markers Loco-regional chemotherapy
The authors are indebted to Cristiana Carniti, MD, PhD for assistance in writing the manuscript.
- 1.Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients. The Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. JCO 1988; 6:147–153Google Scholar
- 14.Bagshawe KD, Rustin GJ. (1995) Circulating tumour markers. In: Peckham M, Pinedo H, Veronesi U, eds. Oxford Textbook of Oncology. Oxford University Press, Oxford, UK, pp 412–420Google Scholar
- 15.Weiss SW. World Health Organization Istological Classification of tomors. Histological typing of soft tissue tumours. 2nd edition. Berlin: Springer-Verlag, 1994Google Scholar
- 16.Oken MM, Creech RH, Tormey, et al. Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649–655Google Scholar
- 17.Esquivel JE, Sugarbaker PH. Elective surgery in recurrent colon cancer with peritoneal seeding: when to and when not to. Cancer Ther 1998; 1:321–325Google Scholar
- 18.Jaquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 1996; 15:49–58Google Scholar
- 19.Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205–216PubMedCrossRefGoogle Scholar
- 20.Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Soc 1958; 53:457–481Google Scholar
- 21.Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34:187–220Google Scholar
- 28.Rustin GJS, Timmers P, Nelstrop P, Shreeves G, Bentzen SM, Baron B, et al. Comparison of CA-125 and Standard Definitions of Progression of Ovarian Cancer in the Intergroup Trial of Cisplatin and Paclitaxel Versus Cisplatin and Cyclophosphamide Journal of Clinical Oncology 2006; 24:45–51PubMedCrossRefGoogle Scholar
- 33.Almudevar Bercero E, Garcia-Rostan Perez GM, Garcia Bragado F, et al. Prognostic value of high serum levels of CA-125 in malignant secretory peritoneal mesotheliomas affecting young women. A case report with differential diagnosis and review of the literature. Histopathology 1997; 31:267–273PubMedCrossRefGoogle Scholar
- 36.Van Ruth S, Hart AA, Bonfrer JM, et al. Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2002; 9:961–967PubMedCrossRefGoogle Scholar